Brief: Vaxart Long-Term Goal Is To Protect Infants Through Passive Antibody Transfer
30/04/2024 13:58
April 30 (Reuters) - Vaxart Inc VXRT.O :
* VAXART ANNOUNCES POSITIVE RESULTS FOR ITS BIVALENT
NOROVIRUS
VACCINE CANDIDATE IN LACTATING MOTHERS
* VAXART INC - LONG-TERM GOAL IS TO PROVIDE PROTECTION TO
INFANTS
THROUGH PASSIVE ANTIBODY TRANSFER
* VAXART INC - ANTIBODY RISE OBSERVED IN LACTATING MOTHERS
AND IN
THEIR BREAST MILK
Source text for Eikon: ID:nGNX1Qtd6l
Further company coverage: VXRT.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Vaxart
See all newsBrief: Vaxart Expands Intellectual Property Portfolio With European Patent Protecting Proprietary Norovirus Vaccine Technology
Vaxart Q2 revenue falls on lower government contract income
Brief: Vaxart Q2 Net Income USD -13.494 Million
Brief: Vaxart Enters Cooperation Agreement With Stockholder Group And Announces Board And Corporate Governance Enhancements
Vaxart Q1 revenue more than doubles on government contracts